Copyright
©The Author(s) 2023.
World J Gastroenterol. Oct 14, 2023; 29(38): 5428-5434
Published online Oct 14, 2023. doi: 10.3748/wjg.v29.i38.5428
Published online Oct 14, 2023. doi: 10.3748/wjg.v29.i38.5428
Figure 2 Disease activity, laboratory findings, and therapy.
ADA: Adalimumab; ATA: Antibodies to adalimumab; PCDAI: Pediatric Crohn’s Disease Activity Index.
- Citation: Ancona S, Signa S, Longo C, Cangemi G, Carfora R, Drago E, La Rosa A, Crocco M, Chiaro A, Gandullia P, Arrigo S. Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease. World J Gastroenterol 2023; 29(38): 5428-5434
- URL: https://www.wjgnet.com/1007-9327/full/v29/i38/5428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i38.5428